St. Joseph’s Companion Aspirin
This article was originally published in The Tan Sheet
McNeil Consumer & Specialty Pharmaceuticals introduces specially packaged St. Joseph's aspirin for consumers to take in the event of a suspected heart attack, the firm announces Aug. 23. Companion Aspirin, which began shipping in July, includes three individual packets, each containing two chewable tablets of aspirin 81 mg. Each individual packet provides the "emergency" dose recommended at onset of heart attack symptoms in an easy-to-open pouch and will retail for $1.00, McNeil notes. FDA approved modified labeling for aspirin in 1998, allowing language recommending aspirin use during suspected acute myocardial infarction (1"The Tan Sheet" Oct. 26, 1998, p. 4)...
You may also be interested in...
FDA's final rule on professional labeling for aspirin includes an indication for aspirin use during suspected acute myocardial infarction as soon as a heart attack is suspected, as directed by health care personnel.
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.